Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/16/2012EP2452683A2 Methods for treating atherosclerosis
05/16/2012EP2452682A1 Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
05/16/2012EP2452681A1 Salts of 13a-(s)desoxytylophorinine, preparation methods and pharmaceutical compositions and uses thereof
05/16/2012EP2452680A1 Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement
05/16/2012EP2452679A1 Cytoprotective agent
05/16/2012EP2452678A2 Pulsatile-release pharmaceutical formulation of dexlansoprazole
05/16/2012EP2452675A1 Buccal spray containing sildenafil
05/16/2012EP2452674A2 Compositions and methods for increasing blood platelet levels in humans
05/16/2012EP2452673A2 Chitosan gel for dermatological use, production method therefor and use of same
05/16/2012EP2452672A2 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
05/16/2012EP2452670A1 Conveniently implantable sustained release drug compositions
05/16/2012EP2452669A1 Ophthalmic composition
05/16/2012EP2452577A1 Aqueous solution of phytin and use of said solution for preparing a liquid food supplement or a cosmetic composition
05/16/2012EP2451974A2 Oligonucleotide-based compounds as inhibitors of toll-like receptors
05/16/2012EP2451952A2 Sparc antisense compositions and uses thereof
05/16/2012EP2451945A1 Oncolytic viruses and methods for treating neoplastic disorders
05/16/2012EP2451944A1 Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
05/16/2012EP2451822A1 New antiviral compounds useful for the treatment or the prevention of epidemic keratoconjonctivitis
05/16/2012EP2451817A1 Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
05/16/2012EP2451816A1 Crystalline form of prasugrel hydrobromide, preparation and application thereof
05/16/2012EP2451815A1 INDUCTION OF alpha-HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES
05/16/2012EP2451814A2 Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
05/16/2012EP2451813A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
05/16/2012EP2451812A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
05/16/2012EP2451811A1 Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
05/16/2012EP2451807A1 Cyclic triazo sodium channel blockers
05/16/2012EP2451805A1 A crystalline form of posaconazole
05/16/2012EP2451802A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
05/16/2012EP2451800A1 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
05/16/2012EP2451796A1 Tofa analogs useful in treating dermatological disorders or conditions
05/16/2012EP2451795A1 Compositions and methods for enhancing virus efficacy
05/16/2012EP2451794A2 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
05/16/2012EP2451790A1 Histone deacetylase inhibitors
05/16/2012EP2451788A1 Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl]-benzoylamino} -4-methylen -penta nedioic acid
05/16/2012EP2451787A1 Polymorph of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]
05/16/2012EP2451783A2 Lonidamine analogues for fertility management
05/16/2012EP2451782A1 Dual-acting pyrazole antihypertensive agents
05/16/2012EP2451779A2 Etomidate analogues that do not inhibit adrenocortical steroid synthesis
05/16/2012EP2451773A2 Novel polymorphic form of teriflunomide salts
05/16/2012EP2451771A1 Salts of rasagiline and pharmaceutical preparations thereof
05/16/2012EP2451482A1 Combination therapy for the treatment of diabetes
05/16/2012EP2451479A1 Bi-specific digoxigenin binding antibodies
05/16/2012EP2451463A2 Ophthalmic ethyleneoxide butyleneoxide block copolymer compositions
05/16/2012EP2451462A1 Inhibiting inflammation with milk oligosaccharides
05/16/2012EP2451461A1 Novel nucleic acid prodrugs and methods of use thereof
05/16/2012EP2451460A1 Liquid pharmaceutical form of alkylphosphocholine and method of preparing same
05/16/2012EP2451459A1 Method of reducing multi-drug resistance using inositol tripyrophosphate
05/16/2012EP2451458A2 Pharmaceutical compositions and solid forms
05/16/2012EP2451457A1 Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
05/16/2012EP2451456A1 Combined preparation for use as a medicament
05/16/2012EP2451455A2 Rxr agonist compounds and methods
05/16/2012EP2451454A1 Method of treating age related disorders
05/16/2012EP2451453A1 Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
05/16/2012EP2451452A1 USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
05/16/2012EP2451451A1 Hdac 6 inhibitor-based methods for treating cancer
05/16/2012EP2451450A1 New inhibitors of proline racemase enzymes
05/16/2012EP2451449A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
05/16/2012EP2451445A2 Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
05/16/2012EP2451444A1 Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy]- 7-0x0-6, 7- dihydro- 5h- phyrrolo [3, 4-b]pyrazine
05/16/2012EP2451439A1 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition
05/16/2012EP2451438A2 Pharmaceutical composition for a hepatitis c viral protease inhibitor
05/16/2012EP2451436A1 Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes
05/16/2012EP2451299A1 Methods and compositions for treating thyroid-related medical conditions with reduced folates
05/16/2012EP2451284A1 Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor
05/16/2012EP2451281A1 Tetrahydronapthyridine orexin receptor antagonists
05/16/2012EP2451280A1 Method of wound healing and scar modulation
05/16/2012EP2451279A1 Compounds, compositions, and methods for preventing metastasis of cancer cells
05/16/2012EP2451278A2 Inhibitors of filovirus entry into host cells
05/16/2012EP2451276A1 Methods of treating pdnv and ponv with extended release ondansetron compositions
05/16/2012EP2451274A1 Pharmaceutical compositions
05/16/2012EP2451273A1 Compositions and methods for inhibition of cancers
05/16/2012EP2313413B1 Pyrazolo [1, 5-a] pyrimidine derivatives
05/16/2012EP2307383B1 Aminotetrahydroindazoloacetic acids
05/16/2012EP2305645B1 Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
05/16/2012EP2303251B1 New combination for use in the treatment of inflammatory disorders
05/16/2012EP2285214B1 Rasagiline soft gelatin capsules
05/16/2012EP2275430B1 Hemifumarate of a pyrazole derivative
05/16/2012EP2268648B1 Crystalline (6R,7R)-7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert- butoxycarbonyl-2-oxo-[1,3]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
05/16/2012EP2268628B1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
05/16/2012EP2268625B1 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof
05/16/2012EP2268274B1 Vitamin e derivatives and their uses
05/16/2012EP2254573B1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
05/16/2012EP2244693B1 Agent for intra-articular injection
05/16/2012EP2219643B1 Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener
05/16/2012EP2183247B1 New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl]1h- indole- 5 -carbonitrile citrate
05/16/2012EP2144902B1 [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
05/16/2012EP2142200B1 Homeopathy-based formulation
05/16/2012EP2131837B1 Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
05/16/2012EP2124919B1 5,5'-(sulfonyldiemethylene)diuracil for modulating bone formation and mineralization
05/16/2012EP2120570B1 Treatment of comorbid premature ejaculation and erectile dysfunction
05/16/2012EP2114147B1 Reducing side effects of tramadol
05/16/2012EP2086940B1 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
05/16/2012EP2059139B1 Tasteless nutritional supplement containing free amino acids
05/16/2012EP2046798B1 Furo [3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
05/16/2012EP2044028B1 Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
05/16/2012EP2043646B1 (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE
05/16/2012EP2012779B1 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors
05/16/2012EP1997486B1 Therapeutic agent for functional brain disease
05/16/2012EP1990052B1 Pharmaceutical package comprising 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl and a desiccant.
05/16/2012EP1934233B1 Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
1 ... 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 ... 7860